Atrion Co. (NASDAQ:ATRI) Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its position in Atrion Co. (NASDAQ:ATRI – Get Rating) by 3.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,640 shares of the medical instruments supplier’s stock after acquiring an additional 54 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Atrion were worth $926,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its stake in shares of Atrion by 0.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,929 shares of the medical instruments supplier’s stock valued at $1,213,000 after buying an additional 16 shares during the period. Rhumbline Advisers boosted its stake in shares of Atrion by 1.4% in the 2nd quarter. Rhumbline Advisers now owns 5,500 shares of the medical instruments supplier’s stock valued at $3,459,000 after buying an additional 77 shares during the period. Better Money Decisions LLC purchased a new position in shares of Atrion in the 2nd quarter valued at about $63,000. Strs Ohio boosted its stake in shares of Atrion by 9.1% in the 2nd quarter. Strs Ohio now owns 1,200 shares of the medical instruments supplier’s stock valued at $754,000 after buying an additional 100 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Atrion by 2.2% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783 shares of the medical instruments supplier’s stock valued at $6,263,000 after buying an additional 185 shares during the period. 64.90% of the stock is owned by institutional investors and hedge funds.

Atrion Stock Performance

Shares of ATRI opened at $679.00 on Friday. The stock has a 50-day simple moving average of $599.68 and a 200-day simple moving average of $611.78. The stock has a market capitalization of $1.20 billion, a PE ratio of 35.09 and a beta of 0.30. Atrion Co. has a 1 year low of $534.99 and a 1 year high of $783.80.

Atrion (NASDAQ:ATRI – Get Rating) last posted its earnings results on Tuesday, November 8th. The medical instruments supplier reported $4.94 earnings per share for the quarter. The firm had revenue of $44.63 million during the quarter. Atrion had a return on equity of 14.16% and a net margin of 19.24%.

Atrion Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 15th. Investors of record on Thursday, December 1st were paid a dividend of $2.15 per share. This represents a $8.60 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend was Wednesday, November 30th. Atrion’s payout ratio is 44.44%.

Insider Buying and Selling

In related news, CFO Jeffery Strickland sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 26th. The stock was sold at an average price of $675.00, for a total transaction of $675,000.00. Following the completion of the sale, the chief financial officer now owns 1,532 shares in the company, valued at $1,034,100. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 22.65% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, StockNews.com cut Atrion from a “buy” rating to a “hold” rating in a research note on Tuesday, November 8th.

Atrion Company Profile

(Get Rating)

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.